Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.
Fiche publication
Date publication
mars 2017
Journal
BMC medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AVEROUS Gerlinde, Pr BACHELLIER Philippe, Pr NAMER Izzie-Jacques
Tous les auteurs :
Battini S, Faitot F, Imperiale A, Cicek AE, Heimburger C, Averous G, Bachellier P, Namer IJ
Lien Pubmed
Résumé
Pancreatic adenocarcinomas (PAs) have very poor prognoses even when surgery is possible. Currently, there are no tissular biomarkers to predict long-term survival in patients with PA. The aims of this study were to (1) describe the metabolome of pancreatic parenchyma (PP) and PA, (2) determine the impact of neoadjuvant chemotherapy on PP and PA, and (3) find tissue metabolic biomarkers associated with long-term survivors, using metabolomics analysis.
Mots clés
Biomarker, HRMAS, Long-term survival, Metabolomics, NMR, Pancreatic adenocarcinoma
Référence
BMC Med. 2017 Mar;15(1):56